{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:58:37Z","timestamp":1791208717079,"version":"4.1.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Quality of life (QoL), a critical factor for sustaining recovery from alcohol use disorder (AUD), has been examined as an AUD-related outcome in randomized controlled trials (RCTs) that evaluated pharmacotherapy for AUD. This review evaluates the efficacy of this therapy in improving mental and physical health-related QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RCTs were identified across seven databases. Study quality was evaluated using the Cochrane risk-of-bias tool for randomized trials version 2. A systematic review with meta-analysis was conducted. The review adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines and was registered with PROSPERO (CRD420261277890).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen RCTs with 4376 participants were evaluated. Naltrexone was linked to improvements in both mental QoL (d\u2009=\u20090.30, 95% CI: 0.08\u20130.52) and physical QoL (d\u2009=\u20090.16, 95% CI: 0.01\u20130.31). Nalmefene improved physical QoL (d\u2009=\u20090.13, 95% CI: 0.02\u20130.25) but not mental QoL (d\u2009=\u20090.18, 95% CI: \u22120.004 to 0.354). Topiramate showed no improvement in either domain. However, further analysis indicated that topiramate was associated with a small improvement in physical QoL, which could correlate with a reduced percentage of heavy drinking days. Interpret these findings with caution. Acamprosate, sertraline, and psilocybin were associated with improved mental or physical QoL, whereas ketamine, varenicline, levetiracetam XR, and quetiapine were not. Interpretation is limited to single trials\u2014no eligible RCTs reporting the specified QoL outcomes for disulfiram.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Certain medications for AUD are linked with improved mental and physical QoL, but evidence remains limited. Future RCTs should assess QoL and establish whether improvements are clinically meaningful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/alcalc\/agag067","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:58:06Z","timestamp":1790164686000},"source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological interventions for alcohol use disorder on quality of life: a meta-analysis of randomized controlled trials"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9272-2259","authenticated-orcid":false,"given":"Dimy","family":"Fluyau","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Emory University School of Medicine , 201 Dowman Dr, Atlanta, GA 30322 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelambika","family":"Revadigar","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Duke University School of Medicine , 2138 Campus Dr, Durham, NC 27710 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Emory University School of Medicine , 201 Dowman Dr, Atlanta, GA 30322 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100509103551800_ref1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1136\/bmj.322.7299.1417","article-title":"Who should measure quality of life?","volume":"322","author":"Addington-Hall","year":"2001","journal-title":"BMJ."},{"key":"2026100509103551800_ref2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1744-859X-4-5","article-title":"Review of the use of topiramate for treatment of psychiatric disorders","volume":"4","author":"Arnone","year":"2005","journal-title":"Ann General Psychiatry"},{"key":"2026100509103551800_ref3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000371547","article-title":"Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients","volume":"21","author":"Aubin","year":"2015","journal-title":"Eur Addict Res"},{"key":"2026100509103551800_ref4","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ecolind.2014.06.002","article-title":"A conceptual framework for integrated analysis of environmental quality and quality of life","volume":"45","author":"Banzhaf","year":"2014","journal-title":"Ecol Indic"},{"key":"2026100509103551800_ref5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40290-024-00526-x","article-title":"Endpoints for pharmacotherapy trials for alcohol use disorder","volume":"38","author":"Belnap","year":"2024","journal-title":"Pharmaceut Med"},{"key":"2026100509103551800_ref6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1037\/ccp0000750","article-title":"Mechanisms of quality-of-life improvement in treatment for alcohol use disorder","volume":"90","author":"Carlon","year":"2022","journal-title":"J Consult Clin Psychol"},{"key":"2026100509103551800_ref7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0885-3924(94)90129-5","article-title":"Quality of life: concepts and definitions","volume":"9","author":"Cella","year":"1994","journal-title":"J Pain Symptom Manag"},{"key":"2026100509103551800_ref8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1034\/j.1399-5618.2001.30501.x","article-title":"The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder","volume":"3","author":"Chengappa","year":"2001","journal-title":"Bipolar Disord"},{"key":"2026100509103551800_ref9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_474_22","article-title":"Impact of hyperthyroidism and its treatment on the outcome of mental health, occupational functioning, and quality of life: a naturalistic, prospective study","volume":"65","author":"Chopra","year":"2023","journal-title":"Indian J Psychiatry"},{"key":"2026100509103551800_ref10","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587"},{"key":"2026100509103551800_ref11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4103\/jehp.jehp_248_23","article-title":"Quality of life in patients with alcohol use disorders admitted to de-addiction centers using WHOQOL-BREF scale\u2014a cross-sectional study","volume":"12","author":"Colaco","year":"2023","journal-title":"J Educ Health Promot"},{"key":"2026100509103551800_ref12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2215-0366(20)30489-2","article-title":"Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial","volume":"8","author":"Collins","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2026100509103551800_ref13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s002130100909","article-title":"Depot naltrexone: long-lasting antagonism of the effects of heroin in humans","volume":"159","author":"Comer","year":"2002","journal-title":"Psychopharmacology"},{"key":"2026100509103551800_ref14","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1176\/ajp.142.9.1081","article-title":"Naltrexone-induced dysphoria in former opioid addicts","volume":"142","author":"Crowley","year":"1985","journal-title":"Am J Psychiatry"},{"key":"2026100509103551800_ref15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1080\/j.1440-1614.2004.01469.x","article-title":"Alcohol dependence: the impact of cognitive behaviour therapy with or without naltrexone on subjective health status","volume":"38","author":"Feeney","year":"2004","journal-title":"Aust N Z J Psychiatry"},{"key":"2026100509103551800_ref16","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/j.1530-0277.2011.01716.x","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients","volume":"36","author":"Fertig","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"2026100509103551800_ref17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"2026100509103551800_ref18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jsat.2006.09.008","article-title":"Reduction in heavy drinking as a treatment outcome in alcohol dependence","volume":"33","author":"Gastfriend","year":"2007","journal-title":"J Subst Abus Treat"},{"key":"2026100509103551800_ref19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12888-023-04577-3","article-title":"The clustering of physical health conditions and associations with co-occurring mental health problems and problematic alcohol use: a cross-sectional study","volume":"23","author":"Gomez","year":"2023","journal-title":"BMC Psychiatry"},{"key":"2026100509103551800_ref20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry"},{"key":"2026100509103551800_ref21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/SAR.S431270","article-title":"Nalmefene hydrochloride: potential implications for treating alcohol and opioid use disorder","volume":"15","author":"Green","year":"2024","journal-title":"Subst Abus Rehabil"},{"key":"2026100509103551800_ref22","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026100509103551800_ref23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/alcalc\/agg124","article-title":"Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial","volume":"38","author":"Gual","year":"2003","journal-title":"Alcohol Alcohol"},{"key":"2026100509103551800_ref24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1176\/appi.ajp.21090963","article-title":"Defining recovery from alcohol use disorder: development of an NIAAA research definition","volume":"179","author":"Hagman","year":"2022","journal-title":"Am J Psychiatry"},{"key":"2026100509103551800_ref25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"2026100509103551800_ref26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"2026100509103551800_ref27","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA."},{"key":"2026100509103551800_ref28","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","article-title":"Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial","volume":"168","author":"Johnson","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026100509103551800_ref29","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1007\/s11136-017-1631-4","article-title":"Viability of the World Health Organization quality of life measure to assess changes in quality of life following treatment for alcohol use disorder","volume":"26","author":"Kirouac","year":"2017","journal-title":"Qual Life Res"},{"key":"2026100509103551800_ref30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/add.16421","article-title":"Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: a systematic review and network meta-analysis","volume":"119","author":"Kotake","year":"2024","journal-title":"Addiction."},{"key":"2026100509103551800_ref31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/acer.15118","article-title":"Medications for treating alcohol use disorder: a narrative review","volume":"47","author":"Kranzler","year":"2023","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"2026100509103551800_ref32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism","volume":"171","author":"Kranzler","year":"2014","journal-title":"Am J Psychiatry"},{"key":"2026100509103551800_ref33","doi-asserted-by":"publisher","first-page":"108762","DOI":"10.1016\/j.drugalcdep.2021.108762","article-title":"Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder","volume":"225","author":"Kranzler","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2026100509103551800_ref34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41386-020-00945-9","article-title":"Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder","volume":"46","author":"Kranzler","year":"2021","journal-title":"Neuropsychopharmacology."},{"key":"2026100509103551800_ref35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12955-022-02058-x","article-title":"Determinants of health-related quality of life in recently detoxified patients with severe alcohol use disorder","volume":"20","author":"Lahbairi","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"2026100509103551800_ref36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/08039488.2013.852242","article-title":"Health-related quality of life in alcohol dependence: a systematic literature review with a specific focus on the role of depression and other psychopathology","volume":"68","author":"Levola","year":"2014","journal-title":"Nord J Psychiatry"},{"key":"2026100509103551800_ref37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.drugalcdep.2013.06.032","article-title":"Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial","volume":"133","author":"Likhitsathian","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"2026100509103551800_ref38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","article-title":"A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients","volume":"36","author":"Litten","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"2026100509103551800_ref39","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"J Addict Med"},{"key":"2026100509103551800_ref40","doi-asserted-by":"publisher","first-page":"s3","DOI":"10.1111\/j.1521-0391.2003.tb00492.x","article-title":"Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence","volume":"12","author":"Littleton","year":"2003","journal-title":"Am J Addict"},{"key":"2026100509103551800_ref41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1176\/appi.prcp.20220023","article-title":"Multidimensional quality of life across the spectrum of alcohol use behavior","volume":"4","author":"Luk","year":"2022","journal-title":"Psychiatr Res Clin Pract"},{"key":"2026100509103551800_ref42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.2340\/16501977-0203","article-title":"A qualitative study of quality of life after stroke: the importance of social relationships","volume":"40","author":"Lynch","year":"2008","journal-title":"J Rehabil Med"},{"key":"2026100509103551800_ref43","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol Psychiatry"},{"key":"2026100509103551800_ref44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1360-0443.2009.02792.x","article-title":"Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial","volume":"105","author":"Martinotti","year":"2010","journal-title":"Addiction."},{"key":"2026100509103551800_ref45","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1177\/0269881109102623","article-title":"Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial","volume":"24","author":"Martinotti","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2026100509103551800_ref46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","article-title":"Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation","volume":"40","author":"Mason","year":"2006","journal-title":"J Psychiatr Res"},{"key":"2026100509103551800_ref47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/10550490290087929","article-title":"Naltrexone and dysphoria: fact or myth?","volume":"11","author":"Miotto","year":"2002","journal-title":"Am J Addict"},{"key":"2026100509103551800_ref48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/pcn.12914","article-title":"Nalmefene in alcohol-dependent patients with a high drinking risk: randomized controlled trial","volume":"73","author":"Miyata","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"2026100509103551800_ref49","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"Open Med"},{"key":"2026100509103551800_ref50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4088\/jcp.v69n0308","article-title":"Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence","volume":"69","author":"Muhonen","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2026100509103551800_ref51","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1176\/appi.ajp.20240470","article-title":"A randomized clinical trial of prolonged exposure therapy with and without topiramate for comorbid PTSD and alcohol use disorder","volume":"182","author":"Norman","year":"2025","journal-title":"Am J Psychiatry"},{"key":"2026100509103551800_ref52","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1001\/jamapsychiatry.2014.3053","article-title":"Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial","volume":"72","author":"Oslin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2026100509103551800_ref53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/0971-8990.164826","article-title":"Tracing the journey of disulfiram: from an unintended discovery to a treatment option for alcoholism","volume":"20","author":"Pal","year":"2015","journal-title":"J Ment Health Hum Behav"},{"key":"2026100509103551800_ref54","doi-asserted-by":"publisher","first-page":"e1001924","DOI":"10.1371\/journal.pmed.1001924","article-title":"Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials","volume":"12","author":"Palpacuer","year":"2015","journal-title":"PLoS Med"},{"key":"2026100509103551800_ref55","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/j.1530-0277.2008.00843.x","article-title":"Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients","volume":"33","author":"Pettinati","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"2026100509103551800_ref56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jsat.2014.11.007","article-title":"Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up","volume":"52","author":"Ponizovsky","year":"2015","journal-title":"J Subst Abus Treat"},{"key":"2026100509103551800_ref57","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11136-023-03522-x","article-title":"Alcohol consumption and health-related quality of life in regional, rural and metropolitan Australia: analysis of cross-sectional data from the Community Health and Rural\/Regional Medicine (CHARM) study","volume":"33","author":"Redwood","year":"2024","journal-title":"Qual Life Res"},{"key":"2026100509103551800_ref58","doi-asserted-by":"publisher","first-page":"103149","DOI":"10.1016\/j.eclinm.2025.103149","article-title":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial","volume":"82","author":"Rieser","year":"2025","journal-title":"EClinicalMedicine."},{"key":"2026100509103551800_ref59","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1111\/acer.70193","article-title":"High- and low-dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: a randomized control trial","volume":"49","author":"Robinson","year":"2025","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"2026100509103551800_ref60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jad.2018.08.052","article-title":"Toward a very brief quality of life enjoyment and satisfaction questionnaire","volume":"242","author":"Rush","year":"2019","journal-title":"J Affect Disord"},{"key":"2026100509103551800_ref61","first-page":"111","article-title":"Naltrexone utility in depressed alcoholics","volume":"34","author":"Salloum","year":"1998","journal-title":"Psychopharmacol Bull"},{"key":"2026100509103551800_ref62","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/j.1530-0277.2010.01270.x","article-title":"A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium or divalproex in bipolar I patients with coexisting alcohol dependence","volume":"34","author":"Stedman","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"key":"2026100509103551800_ref63","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"2026100509103551800_ref64","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.addbeh.2014.07.010","article-title":"Differences between abstinent and non-abstinent individuals in recovery from alcohol use disorders","volume":"39","author":"Subbaraman","year":"2014","journal-title":"Addict Behav"},{"key":"2026100509103551800_ref65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/ajad.12346","article-title":"A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder","volume":"25","author":"Sylvia","year":"2016","journal-title":"Am J Addict"},{"key":"2026100509103551800_ref66","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1046\/j.1528-1157.2001.41700.x","article-title":"Postmarketing experience with topiramate and cognition","volume":"42","author":"Tatum","year":"2001","journal-title":"Epilepsia."},{"key":"2026100509103551800_ref67","volume-title":"StatPearls [Internet]","author":"Teoli","year":"2023"},{"key":"2026100509103551800_ref68","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJM199603283341306","article-title":"Assessment of quality-of-life outcomes","volume":"334","author":"Testa","year":"1996","journal-title":"N Engl J Med"},{"key":"2026100509103551800_ref69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/HRP.0b013e31827fd8aa","article-title":"The importance of quality of life in patients with alcohol abuse and dependence","volume":"21","author":"Ugochukwu","year":"2013","journal-title":"Harv Rev Psychiatry"},{"key":"2026100509103551800_ref70","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1530-0277.1997.tb03855.x","article-title":"Alcohol use disorders, consumption patterns, and health-related quality of life of primary care patients","volume":"21","author":"Volk","year":"1997","journal-title":"Alcohol Clin Exp Res"},{"key":"2026100509103551800_ref71","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1111\/acer.13897","article-title":"Drinking risk level reductions associated with improvements in physical health and quality of life among individuals with alcohol use disorder","volume":"42","author":"Witkiewitz","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"2026100509103551800_ref72","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/JCP.0b013e3182726764","article-title":"A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder","volume":"32","author":"Witte","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"2026100509103551800_ref73","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/s0895-4356(98)00179-6","article-title":"Assessing quality of life in clinical research: from where have we come and where are we going?","volume":"52","author":"Wood-Dauphinee","year":"1999","journal-title":"J Clin Epidemiol"},{"key":"2026100509103551800_ref74","doi-asserted-by":"publisher","first-page":"pyaf056","DOI":"10.1093\/ijnp\/pyaf056","article-title":"Antidepressant efficacy of ketamine plus naltrexone for major depression comorbid with alcohol use disorder: a randomized controlled trial","volume":"28","author":"Yoon","year":"2025","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/61\/6\/agag067\/71603225\/agag067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/61\/6\/agag067\/71603225\/agag067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:10:47Z","timestamp":1791205847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/alcalc\/article\/doi\/10.1093\/alcalc\/agag067\/8864903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9,20]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agag067","relation":{},"ISSN":["0735-0414","1464-3502"],"issn-type":[{"value":"0735-0414","type":"print"},{"value":"1464-3502","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,20]]},"article-number":"agag067"}}